
Investments
66Portfolio Exits
14Partners & Customers
10Service Providers
1About Bristol-Myers Squibb
Bristol-Myers Squibb (NYSE: BMY) is a global biopharmaceutical company committed to discovering, developing, and delivering medicines that help patients prevail over serious diseases. The company was founded in 1887 and is based in New York, New York.

Want to inform investors similar to Bristol-Myers Squibb about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Bristol-Myers Squibb
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Bristol-Myers Squibb in 1 Expert Collection, including Fortune 500 Investor list.
Fortune 500 Investor list
590 items
This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.
Research containing Bristol-Myers Squibb
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Bristol-Myers Squibb in 2 CB Insights research briefs, most recently on Oct 28, 2022.

Latest Bristol-Myers Squibb News
Jun 5, 2023
Approximately 7,000 people will now be able to choose this treatment for obstructive HCM on the NHS. Bristol-Myers Squibb’s mavacamten will be used to treat obstructive hypertrophic cardiomyopathy. Credit: Africa Studio via Shutterstock.com. The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of Bristol-Myers Squibb’s mavacamten (Camzyos) as an add-on to standard care to control symptoms of obstructive hypertrophic cardiomyopathy (HCM). The symptoms of obstructive HCM include fatigue, palpitations and shortness of breath. Recommended Reports Camzyos is an allosteric and reversible inhibitor that is selective for cardiac myosin. It has also been approved in the US to treat symptomatic New York Heart Association class II-III obstructive HCM in adult patients, improving their functional capacity and symptoms. The combination of mavacamten and standard care was found to be more effective than standard care alone and could prevent or delay the need for invasive surgery. NICE medicines evaluation director Helen Knight stated: “Obstructive hypertrophic cardiomyopathy is a disease for which, until now, there has been no specific treatment that targets its underlying cause. “It has a very high and wide-ranging impact on quality of life and because it can develop at any age, it can occur in younger people who may formerly have had very active lifestyles. “The treatments currently used to try to manage symptoms are associated with side effects and are often ineffective. “We’re therefore pleased to be able to recommend a treatment that has the potential to alter the course of obstructive hypertrophic cardiomyopathy and offer greater hope to people with it.” In April 2023, the European Medicines Agency’s committee for medicinal products for human use recommended approval of Camzyos for the same indication. Share this article
Bristol-Myers Squibb Investments
66 Investments
Bristol-Myers Squibb has made 66 investments. Their latest investment was in TORL BioTherapeutics as part of their Series B on April 4, 2023.

Bristol-Myers Squibb Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/13/2023 | Series B | TORL BioTherapeutics | $158M | Yes | 2 | |
3/15/2023 | Series A - II | Mediar Therapeutics | $85M | Yes | 6 | |
2/10/2023 | Series A - II | Allyx Therapeutics | $2.31M | No | 1 | |
1/26/2023 | Series A - II | |||||
11/29/2022 | Series A |
Date | 4/13/2023 | 3/15/2023 | 2/10/2023 | 1/26/2023 | 11/29/2022 |
---|---|---|---|---|---|
Round | Series B | Series A - II | Series A - II | Series A - II | Series A |
Company | TORL BioTherapeutics | Mediar Therapeutics | Allyx Therapeutics | ||
Amount | $158M | $85M | $2.31M | ||
New? | Yes | Yes | No | ||
Co-Investors | |||||
Sources | 2 | 6 | 1 |
Bristol-Myers Squibb Portfolio Exits
14 Portfolio Exits
Bristol-Myers Squibb has 14 portfolio exits. Their latest portfolio exit was Personal Genome Diagnostics on December 23, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
12/23/2021 | Acquired | 12 | |||
10/1/2021 | IPO | Public | 3 | ||
8/18/2021 | Acquired | 36 | |||
Date | 12/23/2021 | 10/1/2021 | 8/18/2021 | ||
---|---|---|---|---|---|
Exit | Acquired | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 12 | 3 | 36 |
Bristol-Myers Squibb Acquisitions
18 Acquisitions
Bristol-Myers Squibb acquired 18 companies. Their latest acquisition was Turning Point Therapeutics on August 17, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
8/17/2022 | Series D | $144.43M | Acq - P2P | 5 | ||
11/17/2020 | Series B | $94M | Acq - P2P | 8 | ||
8/24/2020 | Series C | $18.8M | Acquired | 10 | ||
11/21/2019 | ||||||
8/3/2017 | Other Venture Capital |
Date | 8/17/2022 | 11/17/2020 | 8/24/2020 | 11/21/2019 | 8/3/2017 |
---|---|---|---|---|---|
Investment Stage | Series D | Series B | Series C | Other Venture Capital | |
Companies | |||||
Valuation | |||||
Total Funding | $144.43M | $94M | $18.8M | ||
Note | Acq - P2P | Acq - P2P | Acquired | ||
Sources | 5 | 8 | 10 |
Bristol-Myers Squibb Partners & Customers
10 Partners and customers
Bristol-Myers Squibb has 10 strategic partners and customers. Bristol-Myers Squibb recently partnered with ONO PHARMACEUTICAL CO on May 5, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
5/16/2023 | Partner | Japan | Personalis, Ono Pharmaceutical, Japan National Cancer Center Partner on Opdivo Rectal Cancer Trial NEW YORK -- Personalis said Tuesday that it has partnered with Ono Pharmaceutical and Japan 's National Cancer Center to assess its minimal residual disease platform in a study of Opdivo in resectable rectal cancer with mismatch repair deficiency . | 1 | |
4/20/2023 | Licensor | Germany | Evotec : Partner Tubulis Announces Strategic License Agreement with Bristol Myers Squibb Evotec-partner Tubulis GmbH and Bristol Myers Squibb today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates . | 9 | |
4/11/2023 | Partner | United States | Foundation Medicine to develop companion diagnostic for Bristol Myers' cancer drug repotrectinib Foundation Medicine said it expanded collaboration with Bristol Myers Squibb to develop a tissue-based test FoundationOne CDx , as a companion diagnostic for Bristol Myers Squibb ' investigational oral cancer drug repotrectinib . | 2 | |
3/20/2023 | Licensor | ||||
3/2/2023 | Partner |
Date | 5/16/2023 | 4/20/2023 | 4/11/2023 | 3/20/2023 | 3/2/2023 |
---|---|---|---|---|---|
Type | Partner | Licensor | Partner | Licensor | Partner |
Business Partner | |||||
Country | Japan | Germany | United States | ||
News Snippet | Personalis, Ono Pharmaceutical, Japan National Cancer Center Partner on Opdivo Rectal Cancer Trial NEW YORK -- Personalis said Tuesday that it has partnered with Ono Pharmaceutical and Japan 's National Cancer Center to assess its minimal residual disease platform in a study of Opdivo in resectable rectal cancer with mismatch repair deficiency . | Evotec : Partner Tubulis Announces Strategic License Agreement with Bristol Myers Squibb Evotec-partner Tubulis GmbH and Bristol Myers Squibb today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates . | Foundation Medicine to develop companion diagnostic for Bristol Myers' cancer drug repotrectinib Foundation Medicine said it expanded collaboration with Bristol Myers Squibb to develop a tissue-based test FoundationOne CDx , as a companion diagnostic for Bristol Myers Squibb ' investigational oral cancer drug repotrectinib . | ||
Sources | 1 | 9 | 2 |
Bristol-Myers Squibb Service Providers
1 Service Provider
Bristol-Myers Squibb has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Acq - P2P | Investment Bank | Financial Advisor |
Service Provider | |
---|---|
Associated Rounds | Acq - P2P |
Provider Type | Investment Bank |
Service Type | Financial Advisor |
Partnership data by VentureSource
Bristol-Myers Squibb Team
165 Team Members
Bristol-Myers Squibb has 165 team members, including current Founder, President, Suresh Poosala.
Name | Work History | Title | Status |
---|---|---|---|
Suresh Poosala | National Institutes of Health, and St. Jude Children's Research Hospital | Founder, President | Current |
Name | Suresh Poosala | ||||
---|---|---|---|---|---|
Work History | National Institutes of Health, and St. Jude Children's Research Hospital | ||||
Title | Founder, President | ||||
Status | Current |
Compare Bristol-Myers Squibb to Competitors
BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, including protein degradation as well as multi-kinase inhibition, to develop treatments that extend and improve the quality-of-life of patients with life-threatening diseases.
DoubleRainbow Biosciences develops technologies rooted in the mechanistic understanding of specialized metabolic systems in plants and other organisms. The firm devises biosynthetic strategies that provide sustainable access to high-value natural products of medicinal or industrial significance.
Luminary is a clinical-stage allogeneic cell therapy company focused on combining advanced receptor design with cell engineering to overcome antigen escape and T-cell dysfunction. Its therapeutic solutions include BAFF CAR-T, Universal Receptor, and a non-viral allogeneic platform. The company was founded in 2019 and is based in Minneapolis, Minnesota.
GI Innovation is a bio-venture company that explores the development of new drugs through the combination of microbiome (human microorganism) and protein drugs.
Kangpu Biomedical is a biopharmaceutical company in the clinical stage, focusing on cancer, autoimmune diseases, inflammation, and other therapeutic areas, mainly based on protein ubiquitination and the degradation and X-Synergy new drug combination technology platform and other proprietary patents.
Immunwork is a pharmaceutical company that focuses on the research, development, and commercialization of new drugs based on its technology platform for treating multiple types of cancer, autoimmune diseases, osteoporosis, and other severe clinical conditions.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.